Diagnosing latent tuberculosis in high-risk individuals: Rising to the challenge in high-burden areas

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 4, 2011, Pages

  Kasprowicz, Victoria O ^a,b,c   Churchyard, Gavin ^d   Lawn, Stephen D ^e,f   Squire, S Bertel ^g   Lalvani, Ajit ^h  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d AURUM INSTITUTE   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CD4 ANTIGEN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ISONIAZID; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; TUBERCULIN;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; CASE FINDING; CD4 LYMPHOCYTE COUNT; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHY; NONHUMAN; PATHOGEN LOAD; POSTPRIMARY TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; TUBERCULIN TEST; TUBERCULOSIS CONTROL;

AFRICA; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; PREDICTIVE VALUE OF TESTS;

EID: 80053527320     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir449     Document Type: Article

References (136)

1. United Nations. The Millenium development goals report 2008. New York, NY: United Nations, 2008. .
2. World Health Organization (WHO). Global tuberculosis control: a short update to the 2009 report. Geneva: WHO, 2009. http:// www.who.int/tb/ publications/global-report/2009/update/tbu-9.pdf. Accessed 1 March 2010.
3. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68:2240-6.
4. Watt CJ, Hosseini SM, Lonnroth K, Williams BG, Dye C. The global epidemiology of tuberculosis. In: Schaaf HS, Zumla IA, eds. Tuberculosisda comprehensive clinical reference. Edinburgh: Elsevier, 2009.
5. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86. (Pubitemid 29384157)
6. Dye C, Williams BG. Eliminating human tuberculosis in the twentyfirst century. J R Soc Interface 2008; 5:653-62. (Pubitemid 351589747)
7. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009; 106:13980-5.
8. World Health Organization (WHO). Global tuberculosis control 2010 report. Geneva: WHO, 2010. www.who.int/tb/publications/ global-report/2010/en/index. html. Accessed 15 March 2011.
9. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-33.
10. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 2010; 14:406-12.
11. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009; 13:39-46.
12. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489-98.
13. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005; 5:819-26. (Pubitemid 41400855)
14. Lawn SD, Edwards DJ, Wood R. Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings. Clin Infect Dis 2010; 50:124-5.
15. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemicdwhen will we act? Lancet 2010; 375:1906-19.
16. World Health Organization (WHO). Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: WHO, 2010. http://www.who.int/hiv/pub/2010progressreport/ summary- en.pdf. Accessed 1 September 2011.
17. World Health Organization (WHO). WHO three I's meeting: report of a joint WHO HIV/AIDS and TB Department meeting. Geneva, Switzerland: WHO, 2008. http://www.who.int/hiv/pub/meetingreports/WHO-3Is-meeting-report.pdf. Accessed 1 September 2011.
18. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33:956-73.
19. Sridhar S, Pollock K, Lalvani A. Redefining latent tuberculosis. Future Microbiology. In Press.
20. Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A. Eur Respir J. 2011; 37:1175-82.
21. Blower SM, McLean AR, Porco TC, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995; 1:815-21.
22. Lawn SD, Zumla A. Lancet 2011; 378:57-72.
23. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50. (Pubitemid 19070537)
24. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301:1535-7. (Pubitemid 37128545)
25. Lawn SD, Ayles H, Egwaga S, et al. Potential utility of empiric tuberculosis treatment for patients with advanced HIV in high HIV-TB burden settings. Int J Tuberc Lung Dis 2011; 15:287-95.
26. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-12. (Pubitemid 44162402)
27. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-16. (Pubitemid 41668999)
28. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-82. (Pubitemid 41759864)
29. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-25.
30. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000: CD001363.
31. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010: CD000171.
32. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011; 2011:980594.
33. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003; 17:2063-70. (Pubitemid 37297154)
34. Apers L, Lynen L, Worodria W, Colebunders R. Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment. Trop Med Int Health 2005; 10:1209-14. (Pubitemid 41789672)
35. Corbett EL, Mallory KF, Grant AD, Churchyard GJ, De Cock KM. HIV-1 infection and risk of tuberculosis after rifampicin treatment. Lancet 2001; 357:957-8. (Pubitemid 32247295)
36. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. AmRev Respir Dis 1979; 119:827-30.
37. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-47. (Pubitemid 33101821)
38. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215-22. (Pubitemid 32142297)
39. Samandari T. Preliminary results of the Botswana isoniazid preventative therapy (IPT) clinical trial (6 vs 36 months). In: Proceedings of the 40th Union World Conference on Lung Health. (Cancun, Mexico). Paris, France: International Union Against Tuberculosis and Lung Disease, 2009.
40. World Health Organization (WHO). WHO guidelines for intensified case finding and isoniazid preventive therapy for tuberculosis for people living with HIV in resource constrained settings. Geneva, Switzerland:WHO, 2010. http://whqlibdoc.who.int/publications/2011/ 9789241500708-eng.pdf. Accessed 1 September 2011.
41. Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010; 88:253-9.
42. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12:744-51. (Pubitemid 43726847)
43. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8:e1000391.
44. van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24:1051-5.
45. Karam F, Mbow F, Fletcher H, et al. Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS One 2008; 3:e1441.
46. Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. J Acquir Immune Defic Syndr 2010; 54:71-7.
47. Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged ≥35 years. Clin Infect Dis 2000; 31: 826-9. (Pubitemid 32295515)
48. American Thoracic Society. Medical Section of the American Lung Association: treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134:355-63.
49. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71:1113-20.
50. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991-1001. (Pubitemid 8380195)
51. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99:465-71.
52. Tedla Z, Nyirenda S, Peeler C, et al. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIVinfected adults in Botswana. Am J Respir Crit Care Med 2010; 182:278-85.
53. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazidrelated fatal hepatitis. West J Med 1996; 164:486-91.
54. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-8. (Pubitemid 29143893)
55. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993; 159:560-4. (Pubitemid 23339480)
56. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494-7.
57. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009; 103:1838-53.
58. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996; 22:683-704. (Pubitemid 26286315)
59. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16:2285-93. (Pubitemid 35449014)
60. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a Tcell- based assay: a prospective cohort study. Lancet 2004; 364: 2196-203. (Pubitemid 40018449)
61. Clark SA, Martin SL, Pozniak A, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007; 150:238-44. (Pubitemid 47609557)
62. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175:514-20. (Pubitemid 46354256)
63. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One 2008; 3:e2489.
64. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131:1898-906. (Pubitemid 46981652)
65. Houk VN, Baker JH, Sorensen K, Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968; 16:26-35.
66. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357:2017-21. (Pubitemid 32592390)
67. Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br Med Bull 2010; 93:69-84.
68. Shams H, Weis SE, Klucar P, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005; 172:1161-8. (Pubitemid 43066653)
69. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-73. (Pubitemid 36398385)
70. Dominguez J, Ruiz-Manzano J, De Souza-Galvao M, et al. Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis. Clin Vaccine Immunol 2008; 15:168-71. (Pubitemid 351966546)
71. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366:1443-51. (Pubitemid 41483810)
72. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB Gold and T-SPOT.TB in children. PLoS One 2008; 3:e2624.
73. Diel R, Loddenkemper R,Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TBGold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest 2009; 135:1010-8.
74. Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Pediatrics 2009; 123:38-43.
75. Richeldi L, Ewer K, Losi M, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170:288-95. (Pubitemid 38971414)
76. Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton- Smith P. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis 2005; 9:1242-7. (Pubitemid 41735604)
77. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170:65-9. (Pubitemid 38997753)
78. Hill PC, Brookes RH, Adetifa IM, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006; 117:1542-8. (Pubitemid 46071380)
79. Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322-8. (Pubitemid 47101028)
80. Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In- Tube test. Pediatrics 2009; 123:30-7.
81. Chun JK, Kim CK, Kim HS, et al. The role of a whole blood interferon-gamma assay for the detection of latent tuberculosis infection in Bacille Calmette-Guerin vaccinated children. Diagn Microbiol Infect Dis 2008; 62:389-94.
82. Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzymelinked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in the Gambia. Clin Infect Dis 2004; 38:966-73. (Pubitemid 38457204)
83. Nakaoka H, Lawson L, Squire SB, et al. Risk for tuberculosis among children. Emerg Infect Dis 2006; 12:1383-8. (Pubitemid 44455214)
84. Okada K, Mao TE, Mori T, et al. Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 2008; 136:1179-87.
85. Mutsvangwa J, Millington KA, Chaka K, et al. Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax 2010; 65:315-20.
86. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 2006; 61:616-20. (Pubitemid 44035143)
87. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-84.
88. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137:952-68.
89. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-70. (Pubitemid 351717577)
90. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cellbased, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149:777-87.
91. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3:e1379.
92. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002; 40:704-6. (Pubitemid 34130912)
93. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferongamma release assay in HIV-1-Infected individuals. Clin Infect Dis 2009; 48:954-62.
94. Kik SV, Franken WPJ, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35:1346-53.
95. Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med 2010; 182:834-40.
96. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int J Tuberculosis Lung Dis 2010; 14:819-27.
97. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-c release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 2010; 5:e10508.
98. del Corral H, París SC, Marín ND, et al. IFN-gamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009; 4:e8257.
99. Diel R, Loddenkemper R, Niemann S,Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood IGRA for developing active TBdan update. Am J Respir Crit Care Med 2011; 183:88-95.
100. Lalvani A, Millington KA. T-cell interferon-gamma release assays: can we do better? Eur Respir J 2008; 32:1428-30.
101. Mahomed H, Hughes EJ, Hawkridge T, et al. Comparison of Mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis 2006; 10:310-6.
102. Dosanjh DP, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008; 148:325-36. (Pubitemid 351665463)
103. Hougardy JM, Schepers K, Place S, et al. Heparin-bindinghemagglutinin- induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007; 2:e926.
104. Vincenti D, Carrara S, De Mori P, et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med 2003; 9:105-11. (Pubitemid 36819966)
105. Leyten EM, Lin MY, Franken KL, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006; 8:2052-60. (Pubitemid 44311602)
106. Demissie A, Leyten EM, Abebe M, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006; 13:179-86. (Pubitemid 43383784)
107. Geluk A, Lin MY, van Meijgaarden KE, et al. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun 2007; 75:2914-21. (Pubitemid 46870172)
108. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010; 36:135-42.
109. Goletti D, Raja A, Syed Ahamed Kabeer B, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS one 2010; 5:e12577.
110. Locht C, Rouanet C, Hougardy JM, Mascart F. How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis. Expert Opin Biol Ther 2007; 7:1665-77. (Pubitemid 350157493)
111. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32:1607-15.
112. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006; 6:417-23.
113. Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosisspecific T cells and antigen load. J Immunol 2007; 178:5217-26. (Pubitemid 46595306)
114. Lalvani A, Millington KA. T cells and tuberculosis: beyond interferongamma. J Infect Dis 2008; 197:941-3.
115. Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 2008; 3:e2858.
116. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39:723-9.
117. Caccamo N, Guggino G, Joosten SA, et al. Multifunctional CD4(1) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:2211-20.
118. Casey R, Blumenkrantz D, Millington KA, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS One 2010; 5:e15619.
119. Day CL, Mkhwanazi N, Reddy S, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008; 197:990-9. (Pubitemid 351590027)
120. Wilkinson KA, Wilkinson RJ. Polyfunctional T cells in human tuberculosis. Eur J Immunol 2010; 40:2139-42.
121. Wu B, Huang C, Kato-Maeda M, et al. Messenger RNA expression of IL-8, FOXP3, and IL-12beta differentiates latent tuberculosis infection from disease. J Immunol 2007; 178:3688-94. (Pubitemid 46417636)
122. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
123. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011; 12:15-22.
124. Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007; 195:357-65. (Pubitemid 46146113)
125. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-55.
126. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17:183-8.
127. Bakir M, Dosanjh DP, Deeks JJ, et al. Use of T cell-based diagnosis of tuberculosis infection to optimize interpretation of tuberculin skin testing for child tuberculosis contacts. Clin Infect Dis 2009; 48:302-12.
128. Dodd PJ, Millington KA, Ghani AC, et al. Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. Am J Epidemiol 2010; 171:1037-45.
129. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9:173-84.
130. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smearnegative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369:2042-9. (Pubitemid 46908825)
131. Getahun H. Meta-analysis to inform the development of a standardised approach for TB screening in HIV-infected patients. In: Proceedings of the 40th Union World Conference on Lung Health (Cancun, Mexico). Paris, France: International Union Against Tuberculosis and Lung Disease, 2009.
132. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-8. (Pubitemid 46988004)
133. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-6.
134. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 2007; 196(suppl 3):S449-56. (Pubitemid 351417238)
135. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675-85.
136. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30:769-82, ix.